Peptide Vaccine: Progress and Challenges - Wikidata - wikimedia - TriplyDB

Peptide Vaccine: Progress and Challenges

Peptide Vaccine: Progress and Challenges

http://www.wikidata.org/entity/Q26851329

about

A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus A Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in Mice Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus Immunological properties of gold nanoparticles A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine.In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A Staphylococcal Enterotoxin B (SEB) Induces Memory CD4 T Cell Anergy in vivo and Impairs Recall Immunity to Unrelated Antigens.Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.Clinical applications of mouse models for breast cancer engaging HER2/neu.Computer-aided design of T-cell epitope-based vaccines: addressing population coverage.Enhancing vaccine effectiveness with delivery technology.Preparation, characterization and immunological evaluation: canine parvovirus synthetic peptide loaded PLGA nanoparticles.Solid-in-oil nanodispersions for transdermal drug delivery systems.Developing immunotherapeutic strategies to target brain tumors.Design of cocktail peptide vaccine against Cytomegalovirus infection.Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications.Peptide-based synthetic vaccines.Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies.Engineering challenges for brain tumor immunotherapy.Development of Peptide Vaccines in Dengue.Antibody production by in vivo RNA transfection.Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.Structure-based Epitope Mapping of Mycobacterium tuberculosis Secretary Antigen MTC28 Method for generation of peptide-specific IgY antibodies directed to Staphylococcus aureus extracellular fibrinogen binding protein epitope.Progress in vaccine development.Short peptide epitope design from hantaviruses causing HFRS.Q-vaxcelerate: A distributed development approach for a new Coxiella burnetii vaccine.Identification and characterization of antibodies elicited by human cystatin C fragment.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.PilVax - a novel peptide delivery platform for the development of mucosal vaccines.Dissolving Microneedle Arrays for Transdermal Delivery of Amphiphilic Vaccines.Immune Response and Partial Protection against Heterologous Foot-and-Mouth Disease Virus Induced by Dendrimer Peptides in Cattle.Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein.Epitope-mapping of the glycoprotein from Crimean-Congo hemorrhagic fever virus using a microarray approach Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant antigens Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy

P2860

Q24261117-31BBE1F0-4DDC-4F13-B592-FC03F8ACC84F Q26700001-33B852BA-DC22-49D0-8F35-2F1CB7761E82 Q28554288-63ADF422-59D4-46FC-A197-6FC3BAD78807 Q28604286-9790A5B1-D8AC-4823-9D98-B547C4C44F73 Q33578950-663AB8E0-3035-47AA-846C-C17C33BC6187 Q34518856-445D90AE-B6BC-4D4F-AF43-6F0AF044049B Q36029040-8CD7BFA2-F30B-4AA2-9B12-E82E80358484 Q36189723-9CA30376-1F32-41B8-836C-580189DECCA2 Q36485395-4ED654D2-7B8D-4BCB-AFB5-9F05DDC0AFDE Q36933639-1A846013-51BC-4CEB-9494-CD34D92C9C0A Q37607675-69FDCB36-5DD2-4E70-AF66-3651D4D2100C Q38554524-ECD80E33-66AE-47F4-977C-BE6FAD836DDC Q38765636-EFB580AA-A999-4FDC-99FE-B04ED337CA70 Q38826606-FF10B747-AAC9-448E-A7F2-0AE56C8BC410 Q38830870-C8CB3BF3-4F87-45B7-8BAA-BCFDD075C0DC Q38851464-5427352C-21A5-4A57-BC76-36E4F9FFE148 Q38859818-2A62F84C-B6E5-4FC7-9FAD-AE3D24B9746E Q38869738-72A8A000-DF99-45E0-B6F9-14B1EA39F188 Q38914295-565A334D-0927-4834-932F-013E82540047 Q39108259-E325A27E-7FF8-4005-8D10-3616D5CD9908 Q39381281-4F91A35B-DF21-4169-8FB3-239C59269891 Q40038715-FB307BA1-F82E-4898-BE89-8A9F268647E2 Q40052131-3940F2A6-D1FD-4837-8215-95DEC2A8B197 Q40248942-23203BBB-2A77-495B-8766-0A15058EC6C3 Q40670691-EB99479C-EA24-4E8B-BF0F-3EECE9AAFDE5 Q41148315-9C109AF6-2928-4815-AF65-3400F895F960 Q41510529-420BE0FB-1AC7-4237-9671-ED09437B3567 Q41698233-F45A3511-1A50-4982-865D-576E3302EE02 Q41929449-685810BC-85ED-4D0A-9131-8674772CC3A0 Q47563579-3EE7923D-37A2-463D-A41E-FF530092ADD9 Q47590580-EF20B096-9422-41C9-9F2B-9E30845DD54D Q48316344-01A8D04C-7970-449C-895C-B201E24838B4 Q48507555-2680B5AD-E24F-4041-89F9-240B15AF4AA5 Q50863077-4C7026E1-71E6-4FAC-88CB-EF655B00FB69 Q55031351-2258A28A-9EB6-403B-A773-E388F53307BB Q55472927-163CE4B4-2B52-4DD2-82C2-0947626C4196 Q56395419-6E991FAC-166B-4B94-B42A-41FF9FFD3443 Q57070723-BA225ABD-E162-4A30-BB18-240A74683BEB Q57175287-A0A68D44-9E19-4E78-BA56-40CC99552C53 Q57177418-B7DF029C-42BD-4384-9262-719ED802F394

P2860

Peptide Vaccine: Progress and Challenges

http://www.wikidata.org/entity/Q26851329

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Peptide Vaccine: Progress and Challenges

@ast

Peptide Vaccine: Progress and Challenges

@en

Peptide Vaccine: Progress and Challenges

@nl

type

label

Peptide Vaccine: Progress and Challenges

@ast

Peptide Vaccine: Progress and Challenges

@en

Peptide Vaccine: Progress and Challenges

@nl

prefLabel

Peptide Vaccine: Progress and Challenges

@ast

Peptide Vaccine: Progress and Challenges

@en

Peptide Vaccine: Progress and Challenges

@nl

P1433

Q26851329-50B139C6-03C4-4756-9CBF-04ECED91B207

P1476

Q26851329-876DFE11-F4E0-49A2-97BA-D9BE464E640B

P2093

Q26851329-1EAAD90C-B83F-4850-9A16-78A88EA476E9

Q26851329-A0F52B93-156B-490E-95A5-D5FD6C641057

Q26851329-ADB93F22-465D-4B9E-8C38-4D22A958C0A3

Q26851329-E9A798EA-F8F5-4368-AEF1-AD76458BBE52

Q26851329-EA9D927E-8E92-4D3B-B05A-7E0150660A31

P2860

Q26851329-00C60C0D-CC10-4DC4-98D5-6E1A6C73FC3D

Q26851329-0101150D-4021-49AB-8BCD-930D6D97CE9E

Q26851329-04E62124-0578-407D-A513-8D9E9D6A9FE9

Q26851329-050CEC13-B3FF-4E77-BCF7-8B408979C5A1

Q26851329-06FEC262-9B3F-4CFF-864B-9249864CC94B

Q26851329-09F4E9A8-8E32-4952-A8D9-0F0329E2EAF4

Q26851329-0A40C0F8-739C-4580-9BEC-E3EBA028E9FF

Q26851329-0A9F8297-74E4-4D16-9E52-725CA35960F9

Q26851329-0B0C1D1F-7BE8-4101-81B7-6CF8FDB12C91

Q26851329-0E69A446-D767-4F6A-BD50-3E4D30A025B7

P304

Q26851329-38804612-737B-4DA4-A6EE-F1616E85CC31

P31

Q26851329-BE06D852-4339-4D54-B15C-539078F1902B

P3181

Q26851329-A9F782B4-BE79-4121-BB07-08C97F2C08A2

P356

Q26851329-45D6FC31-956E-4183-932B-731AEE0FE981

P407

Q26851329-3D963196-EE1C-4069-B936-BD8B3B967632

P433

Q26851329-2BA65F7E-CC1F-4192-B467-4B9A3B5821E9

P478

Q26851329-732C51C1-72F6-425E-B625-7DE81E4C2997

P577

Q26851329-0C64C285-E72C-47B3-8C9B-A4FC9A22CB9C

P5875

Q26851329-F542C771-5311-437F-8D49-46C7B817E089

P698

Q26851329-38BC9839-AB63-47FE-A088-8A949C729F7F

P932

Q26851329-D1596C98-153D-4B3F-9C50-2B18089AA6F1

P3181

P356

VACCINES2030515

P1433

P1476

Peptide Vaccine: Progress and Challenges

@en

P2093

Ashlesh Murthy

http://www.w3.org/2001/XMLSchema#string

Kyle Ramsey

http://www.w3.org/2001/XMLSchema#string

Medha Joshi

http://www.w3.org/2001/XMLSchema#string

Smita Singhania

http://www.w3.org/2001/XMLSchema#string

Weidang Li

http://www.w3.org/2001/XMLSchema#string

P2860

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

MimoDB 2.0: a mimotope database and beyond

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan.

Epitope mapping: the first step in developing epitope-based vaccines.

Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.

P304

515-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1290243

http://www.w3.org/2001/XMLSchema#string

P356

10.3390/VACCINES2030515

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272089216

http://www.w3.org/2001/XMLSchema#string

P698

26344743

http://www.w3.org/2001/XMLSchema#string

P932

4494216

http://www.w3.org/2001/XMLSchema#string